The clinical course of multiple sclerosis

Handbook of Clinical Neurology

Volumn 122, Issue , 2014, Pages 343-369

  Confavreux, Christian ^a   Vukusic, Sandra ^a  

^a HÔPITAL NEUROLOGIQUE   (France)

Author keywords

Adult onset; Benign MS; Childhood onset; Clinical features; Disability; Initial disease course; Natural history; Prognosis; Progression; Relapse rate; Survival

Indexed keywords

ADULT ONSET; ARTICLE; BENIGN MS; CHILDHOOD ONSET; CLINICAL FEATURE; DISABILITY; DISEASE COURSE; HISTORY; HUMAN; INITIAL DISEASE COURSE; MULTIPLE SCLEROSIS; ONSET AGE; PROGNOSIS; PROGRESSION; RECURRENCE RISK; RECURRENT DISEASE; SURVIVAL; TIME;

ADULT ONSET; BENIGN MS; CHILDHOOD ONSET; CLINICAL FEATURES; DISABILITY; INITIAL DISEASE COURSE; NATURAL HISTORY; PROGNOSIS; PROGRESSION; RELAPSE RATE; SURVIVAL;

AGE OF ONSET; DISEASE PROGRESSION; HUMANS; MULTIPLE SCLEROSIS; PROGNOSIS; RECURRENCE; TIME FACTORS;

EID: 84893506450     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-52001-2.00014-5     Document Type: Chapter

References (177)

1. Amato M.P., Ponziani G. A prospective study on the prognosis of MS. Neurol Sci 2000, 21(Suppl):831-838.
2. Amato M.P., Fratiglioni L., Groppi C., et al. Interrater reliabilty in assessing functional systems and disability on Kurtzke scale in MS. Arch Neurol 1988, 45:746-748.
3. Amato M.P., Grimaud J., Achiti I., et al. European validation of a standardized clinical description of MS. J Neurol 2004, 251:1472-1480.
4. Amato M.P., Zipoli V., Goretti B., et al. Benign MS: cognitive, psychological and social aspects in a clinical cohort. J Neurol 2006, 253:1054-1059.
5. Andersson P.B., Waubant E., Gee L., et al. MS that is progressive from the time of onset. Clinical characteristics and progression of disability. Arch Neurol 1999, 56:1138-1142.
6. Barkhof F., Filippi M., Miller D.H., et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite MS. Brain 1997, 120:2059-2069.
7. Beck R.W., Chandler D.L., Cole S.R., et al. Interferon ß-1a for early MS: CHAMPS trial subgroup analyses. Ann Neurol 2002, 51:481-490.
8. Berger T., Rubner P., Schautzer F., et al. Antimyelin antibodies as a predictor of clinically definite MS after a first demyelinating event. N Engl J Med 2003, 349:139-145.
9. Boiko A., Vorobeychik G., Paty D., et al. Early onset MS: a longitudinal study. Neurology 2002, 59:1006-1010.
10. Bonduelle M. Les formes bénignes de la sclérose en plaques. Presse Med 1967, 75:2023-2026.
11. Brain W.R. Prognosis of disseminated sclerosis. Lancet 1936, 2:866-867.
12. Brex P.A., Miszkiel K.A., O'Riordan J.I., et al. Assessing the risk of early MS in patients with clinically isolated syndromes: the role of a follow-up MRI. J Neurol Neurosurg Psychiatry 2001, 70:390-393.
13. Brex P.A., Ciccarelli O., O'Riordan J.I., et al. A longitudinal study of abnormalities on MRI and disability from MS. N Engl J Med 2002, 346:158-164.
14. Broman T., Andersen O., Bergmann L. Clinical studies on MS. I. Presentation of an incidence material from Gothenburg. Acta Neurol Scand 1981, 63:6-33.
15. Bronnum-Hansen H., Koch-Henriksen N., Hyllested K. Survival of patients with MS in Denmark: a nationwide, long-term epidemiologic survey. Neurology 1994, 44:1901-1907.
16. Bronnum-Hansen H., Koch-Henriksen N., Stenager E. Trends in survival and cause of death in Danish patients with MS. Brain 2004, 127:844-850.
17. CHAMPS Study Group MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group. Neurology 2002, 59:998-1005.
18. Charcot J.M. Leçons sur les maladies chroniques du système nerveux. I Des scléroses de la mœlle épinière. Gazette Hôpitaux 1868, 41:405-406. 409.
19. Charcot J.M. Leçons sur les maladies du système nerveux 1872, Delahaye, Paris.
20. Clark V.A., Detels R., Visscher B.R., et al. Factors associated with a malignant or benign course of MS. JAMA 1982, 248:856-860.
21. Cole G.F., Stuart C.A. A long perspective on childhood MS. Dev Med Child Neurol 1995, 37:661-666.
22. Comi G., Filippi M., Barkhof F., et al. Effect of early interferon treatment on conversion to definite MS: a randomised study. Lancet 2001, 357:1576-1582.
23. Confavreux C. L'histoire naturelle de la sclérose en plaques. Etude par informatique de 349 observations 1977, Thèse de Médecine, Université Claude Bernard, Lyon.
24. Confavreux C. Establishment and use of MS registers - EDMUS. Ann Neurol 1994, 36(Suppl):136-139.
25. Confavreux C. Vaccination contre l'hépatite B et sclérose en plaques. Presse Med 2005, 34:1205-1208.
26. Confavreux C. Defining the natural history of MS: the need for complete data and rigorous definitions. Mult Scler 2008, 14:289-291.
27. Confavreux C., Compston A. The natural history of MS. McAlpine's MS 2006, 183-272. Churchill Livingstone Elsevier, London. 4th edn. A. Compston (Ed.).
28. Confavreux C., Paty D.W. Current status of computerization of MS clinical data for research in Europe and North America: the EDMUS / MS-COSTAR connection. Neurology 1995, 45:573-576.
29. Confavreux C., Vukusic S. Age at disability milestones in MS. Brain 2006, 129:595-605.
30. Confavreux C., Vukusic S. Natural history of MS: a unifying concept. Brain 2006, 129:606-616.
31. Confavreux C., Aimard G., Devic M. Course and prognosis of MS assessed by the computerized data processing of 349 patients. Brain 1980, 103:281-300.
32. Confavreux C., Compston D.A.S., Hommes O.R., et al. EDMUS, a European Database for MS. J Neurol Neurosurg Psychiatry 1992, 55:671-676.
33. Confavreux C., Hours M., Moreau T., et al. Clinical databasing in MS: EDMUS and the European effort. Frontiers in MS: clinical research and therapy 1996, 299-312. Martin Dunitz, London. O. Abramsky (Ed.).
34. Confavreux C., Hutchinson M., Hours M.M., et al. Rate of pregnancy-related relapse in multiple sclerosis. N Engl J Med 1998, 339:285-291. the Pregnancy in Multiple Sclerosis Group.
35. Confavreux C., Vukusic S., Moreau T., et al. Relapses and progression of disability in MS. N Engl J Med 2000, 343:1430-1438.
36. Confavreux C., Suissa S., Saddier P., et al. Vaccinations and the risk of relapse in MS. N Engl J Med 2001, 344:319-326.
37. Confavreux C., Vukusic S., Adeleine P. Early clinical predictors and progression of irreversible disability in MS: an amnesic process. Brain 2003, 126:770-782.
38. Confavreux C., Ritleng C., Debouverie M., et al. Defining the natural history of MS: the need for complete data and rigorous definitions. Answer to Tremlett et al. Mult Scler 2008, 14:1144-1147.
39. Cottrell D.A., Kremenchutzky M., Rice G.P.A., et al. The natural history of MS: a geographically based study. 5. The clinical features and natural history of primary progressive MS. Brain 1999, 122:625-639.
40. Cottrell D.A., Kremenchutzky M., Rice G.P.A., et al. The natural history of MS: a geographically based study. 6. Applications to planning and interpretation of clinical therapeutic trials in primary progressive MS. Brain 1999, 122:641-647.
41. Cox D.R. Regression models and life tables. J Roy Statist Soc Ser B 1972, 34:187-220.
42. Detels R., Clark V.A., Valdiviezo N.L., et al. Factors associated with a rapid course of MS. Arch Neurol 1982, 39:337-341.
43. Duquette P., Murray T.J., Pleines J., et al. MS in childhood: clinical profile in 125 patients. J Pediatr 1987, 111:359-363.
44. Ebers G.C. Natural history of MS. McAlpine's MS 1998, 191-221. Churchill Livingstone, London. 3rd edn. A. Compston, G. Ebers, H. Lassmann (Eds.).
45. Engell T. A clinical patho-anatomical study of clinically silent MS. Acta Neurol Scand 1989, 79:428-430.
46. Eriksson M., Andersen O., Runmarker B. Long-term follow-up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive MS. Mult Scler 2003, 9:260-274.
47. Filippi M., Horsfield M.A., Morrissey S.P., et al. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of MS. Neurology 1994, 44:635-641.
48. Fisniku L.K., Brex P.A., Altmann D.R., et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of MS. Brain 2008, 131:808-817.
49. Fog T., Linnemann F. The course of MS in 73 cases with computer designed curves. Acta Neurol Scand 1970, 46(Suppl):1-175.
50. Ford B., Tampieri D., Francis G. Long-term follow-up of acute partial transverse myelopathy. Neurology 1992, 42:250-252.
51. Francis D.A., Bain P., Swan A.V., et al. An assessment of disability rating scales used in MS. Arch Neurol 1991, 48:299-301.
52. Frederiksen J.L., Larsson H.B.W., Olesen J., et al. MRI, VEP, SEP and biothesiometry suggest monosymptomatic acute optic neuritis to be a first manifestation of MS. Acta Neurol Scand 1991, 83:343-350.
53. Georgi W. Multiple sklerose: pathologisch-anatomische Befund multipler sklerose bei klinisch nicht diagnostizierten Krankheiten. Schweiz Med Wochenschr 1961, 91:605-607.
54. Ghezzi A., Deplano V., Faroni J., et al. MS in childhood: clinical features of 149 cases. Mult Scler 1997, 3:43-46.
55. Ghezzi A., Pozzilli C., Liguori M., et al. Prospective study of MS with early onset. Mult Scler 2002, 8:115-118.
56. Gilbert J.J., Sadler M. Unsuspected MS. Arch Neurol 1983, 40:533-536.
57. Glad S., Nyland H., Myhr K.M. Benign MS. Acta Neurol Scand Suppl 2006, 183:55-57.
58. Goodkin D.E., Hertsgaard D., Rudick R.A. Exacerbation rates and adherence to disease type in a prospective followed-up population with MS. Implications for clinical trials. Arch Neurol 1989, 46:1107-1112.
59. Goodkin D.E., Cookfair D., Wende K., et al. Inter- and intra-rater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS). MS Collaborative Research Group. Neurology 1992, 42:859-863.
60. Hawkins S.A., McDonnell G.V. Benign MS? Clinical course, long term follow up, and assessment of prognostic factors. J Neurol Neurosurg Psychiatry 1999, 67:148-152.
61. Hernan M.A., Jick S.S., Olek M.J., et al. Recombinant hepatitis B vaccine and the risk of MS. A prospective study. Neurology 2004, 63:838-842.
62. Hobart J., Lamping D.L., Thompson A. Evaluating neurological outcome measures: the bare essentials. J Neurol Neurosurg Psychiatry 1996, 60:127-130.
63. Hobart J., Lamping D., Fitzpatrick R., et al. The MS Impact Scale (MSIS-29). A new patient-based outcome measure. Brain 2001, 124:962-973.
64. Hynson J.L., Kornberg A.J., Coleman L.T., et al. Clinical and neuroradiological features of acute disseminated encephalomyelitis in children. Neurology 2001, 56:1308-1312.
65. Jacobs L.D., Beck R.W., Simon J.H., et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in MS. N Engl J Med 2000, 343:898-904.
66. Kantarci O., Siva A., Eraksoy M., et al. Survival and predictors of disability in Turkish MS patients. Neurology 1998, 51:765-772.
67. Kaplan E.L., Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
68. Kappos L., Polman C.H., Freedman M.S., et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006, 67:1242-1249.
69. Koch-Henriksen N., Bronnum-Hansen H., Stenager E. Underlying cause of death in Danish patients with MS: results from the Danish MS Registry. J Neurol Neurosurg Psychiatry 1998, 65:56-59.
70. Korteweg T., Tintore M., Uitdehaag B., et al. MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study. Lancet Neurol 2006, 5:221-227.
71. Kremenchutzky M., Cottrell D., Rice G., et al. The natural history of MS: a geographically based study. 7. Progressive-relapsing and relapsing-progressive MS: a re-evaluation. Brain 1999, 122:1941-1949.
72. Kremenchutzky M., Rice G.P., Baskerville J., et al. The natural history of MS: a geographically based study. 9: Observations on the progressive phase of the disease. Brain 2006, 129:584-594.
73. Kuhle J., Pohl C., Mehling M., et al. Lack of association between antimyelin antibodies and progression to MS. N Engl J Med 2007, 356:371-378.
74. Kurtzke J.F. Course of exacerbations of MS hospitalised patients. Arch Neurol Psychiatry 1956, 76:175-184.
75. Kurtzke J.F. On the evaluation of disability in MS. Neurology 1961, 11:686-694.
76. Kurtzke J.F. Further notes on disability evaluation in MS, with scale modifications. Neurology 1965, 15:654-661.
77. Kurtzke J.F. Rating neurological impairment in MS: an expanded disability status scale (EDSS). Neurology 1983, 33:1444-1452.
78. Kurtzke J.F., Beebe G.W., Nagler B., et al. Studies on natural history of MS. 4: Clinical features of the onset bout. Acta Neurol Scand 1968, 44:467-494.
79. Kurtzke J.F., Beebe G.W., Nagler B., et al. Studies on the natural history of MS. V. Long-term survival in young men. Arch Neurol 1970, 22:215-225.
80. Kurtzke J.F., Beebe G.W., Nagler B., et al. Studies on the natural history of MS. 7: Correlates of clinical changes in an early bout. Acta Neurol Scand 1973, 49:379-395.
81. Kurtzke J.F., Beebe G.W., Nagler B., et al. Studies on the natural history of MS. 8: Early prognostic features of the later course of the illness. J Chron Dis 1977, 30:819-830.
82. Lebrun C., Bensa C., Debouverie M., et al. Unexpected MS: follow-up of 30 patients with magnetic resonance imaging and clinical conversion profile. J Neurol Neurosurg Psychiatry 2008, 79:195-198.
83. Lee K.H., Hashimoto S.A., Hooge J.P., et al. Magnetic resonance imaging of the head in the diagnosis of MS: a prospective 2-year follow-up with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 1991, 41:657-660.
84. Lehoczky T., Halasy-Lehoczky M. Forme "bénigne" de la sclérose en plaques. Presse Med 1963, 1:2294-2296.
85. Leibowitz U., Alter M. Clinical factors associated with increased disability in MS. Acta Neurol Scand 1970, 46:53-70.
86. Leibowitz U., Alter M. MS: Clues to its cause 1973, 1-373. North-Holland Publishing Company, Amsterdam.
87. Leibowitz U., Alter M., Halpern L. Clinical studies of MS in Israel. III. Clinical course and prognosis related to age at onset. Neurology 1964, 14:926-932.
88. Leibowitz U., Halpern L., Alter M. Clinical studies of MS in Israel. I. A clinical analysis based on a country-wide survey. Arch Neurol 1964, 10:502-512.
89. Leibowitz U., Kahana E., Alter M. Survival and death in MS. Brain 1969, 92:115-130.
90. Lhermitte F., Marteau R., Gazengel J., et al. The frequency of relapse in MS: a study based on 245 cases. J Neurol 1973, 205:47-59.
91. Liu C., Blumhardt L.D. Disability outcome measures in therapeutic trials of relapsing remitting MS: effects of heterogeneity of disease course in placebo cohorts. J Neurol Neurosurg Psychiatry 2000, 68:450-457.
92. Lublin F.D., Reingold S.C. Defining the clinical course of MS: results of an international survey. Neurology 1996, 46:907-911.
93. Lublin F.D., Baier M., Cutter G. Effect of relapses on development of residual deficit in MS. Neurology 2003, 61:1528-1532.
94. Marie P. Sclérose en plaques et maladies infectieuses. Progrès Méd 1884, 12:287-289. 305-307, 349-351, 365-366.
95. Martinelli V., Comi G., Filippi M., et al. Paraclinical tests in acute-onset optic neuritis: basal data and results of a short follow-up. Acta Neurol Scand 1991, 84:231-236.
96. McAlpine D. The benign form of MS. A study based on 241 cases seen within three years of onset and followed up until the tenth year or more of the disease. Brain 1961, 84:186-203.
97. McAlpine D. The benign form of MS: results of a long-term follow up. Br Med J 1964, 2:1029-1032.
98. McAlpine D., Compston N.D. Some aspects of the natural history of disseminated sclerosis: incidence, course and prognosis; factors affecting onset and course. Q J Med 1952, 21:135-167.
99. McAlpine D., Compston N.D., Lumsden C.E. MS 1955, Livingstone, Edinburgh.
100. McDonald W.I., Compston A., Edan G., et al. Recommended diagnostic criteria for MS: guidelines from the international panel on the diagnosis of MS. Ann Neurol 2001, 50:121-127.
101. McDonnell G.V., Hawkins S.A. Primary progressive MS: a distinct syndrome?. Mult Scler 1996, 2:137-141.
102. McDonnell G.V., Hawkins S.A. Clinical study of primary progressive MS in Northern Ireland, UK. J Neurol Neurosurg Psychiatry 1998, 64:451-454.
103. McDonnell G.V., Cabrera-Gomez J., Calne D.B., et al. Clinical presentation of primary progressive MS 10 years after the incidental finding of typical magnetic resonance imaging brain lesions: the subclinical stage of primary progressive MS may last 10 years. Mult Scler 2003, 9:210-212.
104. McKay R.P., Hirano A. Forms of benign MS: report of two "clinically silent" cases discovered at autopsy. Arch Neurol 1967, 17:588-600.
105. McLean A.R., Berkson J. Mortality and disability in MS. A statistical estimate of prognosis. JAMA 1951, 146:1367-1369.
106. Mews I., Bergmann M., Bunkowski S., et al. Oligodendrocyte and axon pathology in clinically silent MS lesions. Mult Scler 1998, 4:55-62.
107. Midgard R., Albrektsen G., Riise T., et al. Prognostic factors for survival in MS: a longitudinal, population-based study in More and Romsdal, Norway. J Neurol Neurosurg Psychiatry 1995, 58:417-421.
108. Mikaeloff Y., Adamsbaum C., Husson B., et al. MRI prognostic factors for relapse after acute CNS inflammatory demyelination in childhood. Brain 2004, 127:1942-1947.
109. Mikaeloff Y., Suissa S., Vallée L., et al. First episode of acute CNS inflammatory demyelination in childhood: Prognostic factors for MS and disability. J Pediatr 2004, 144:246-252.
110. Mikaeloff Y., Caridade G., Assi S., et al. Prognostic factors for early severity in a childhood MS cohort. Pediatrics 2006, 118:1133-1139.
111. Miller D.H., Ormerod I.E.C., McDonald W.I., et al. The early risk of MS after optic neuritis. J Neurol Neurosurg Psychiatry 1988, 51:1569-1571.
112. Miller D.H., Ormerod I.E.C., Rudge P., et al. The early risk of MS following acute syndromes of the brainstem and spinal cord. Ann Neurol 1989, 26:635-639.
113. Miller D.H., Hornabrook R.W., Purdie G. The natural history of MS: a regional study with some longitudinal data. J Neurol Neurosurg Psychiatry 1992, 55:341-346.
114. Minderhoud J.M., Van der Hoeven J.H., Prange A.J.A. Course and prognosis of chronic progressive MS. Results of an epidemiological study. Acta Neurol Scand 1988, 78:10-15.
115. Morrissey S.P., Miller D.H., Kendall B.E., et al. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of MS. A 5-year follow-up study. Brain 1993, 116:135-146.
116. Müller R. Studies on disseminated sclerosis. With special reference to symptomatology, course and prognosis. Acta Med Scand 1949, 133(Suppl 222):1-214.
117. Müller R. Course and prognosis of disseminated sclerosis in relation to age at onset. Arch Neurol Psychiatry 1951, 66:561-570.
118. Myhr K.M., Riise T., Vedeler C., et al. Disability and prognosis in MS: demographic and clinical variables important for the ability to walk and awarding of disability pension. Mult Scler 2001, 7:59-65.
119. Noseworthy J.H., Vandenvoort M.K., Wong C.J., et al. Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a MS clinical trial. The Canadian Cooperation MS Study Group. Neurology 1990, 40:971-975.
120. O'Riordan J.I., Thompson A.J., Kingsley D.P.E., et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain 1998, 121:495-503.
121. Panelius M. Studies on epidemiological, clinical and etiological aspects of MS. Acta Neurol Scand 1969, 45(Suppl 39):1-82.
122. Paty D.W., Oger J.J., Kastrukoff L.F., et al. MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding and CT. Neurology 1988, 38:180-185.
123. Patzold U., Pocklington P.R. Course of MS. First results of a prospective study carried out of 102MS patients from 1976-1980. Acta Neurol Scand 1982, 65:248-266.
124. Phadke J.G. Survival pattern and cause of death in patients with MS: results from an epidemiological survey in north-east Scotland. J Neurol Neurosurg Psychiatry 1987, 50:523-531.
125. Phadke J.G. Clinical aspects of MS in north-east Scotland with particular reference to its course and prognosis. Brain 1990, 113:1597-1628.
126. Pittock S.J., Mayr W.T., McClelland R.L., et al. Change in MS-related disability in a population-based cohort: a 10-year follow-up study. Neurology 2004, 62:51-59.
127. Pittock S.J., Mayr W.T., McClelland R.L., et al. Disability profile of MS did not change over 10 years in a population-based prevalence cohort. Neurology 2004, 62:601-606.
128. Pittock S.J., McClelland R.L., Mayr W.T., et al. Clinical implications of benign MS: a 20-year population-based follow-up study. Ann Neurol 2004, 56:303-306.
129. Polman C.H., Reingold S.C., Edan G., et al. Diagnostic criteria for MS: 2005 revisions to the 'McDonald criteria'. Ann Neurol 2005, 58:840-846.
130. Polman C.H., Reingold S.C., Banwell B., et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2010, 69:292-302.
131. Poser S. MS. An analysis of 812 cases by means of electronic data processing 1978, Springer-Verlag, Berlin.
132. Poser S., Bauer H.J., Poser W. Prognosis of MS. Results from an epidemiological area in Germany. Acta Neurol Scand 1982, 65:347-354.
133. Poser S., Raun N.E., Poser W. Age at onset, initial symptomatology and the course of MS. Acta Neurol Scand 1982, 66:355-362.
134. Poser C.M., Paty D.W., Scheinberg L., et al. New diagnostic criteria for MS: guidelines for research protocols. Ann Neurol 1983, 13:227-231.
135. Renoux C., Vukusic S., Mikaeloff Y., et al. Natural history of MS with childhood onset. N Engl J Med 2007, 356:2603-2613.
136. Riise T., Gronning M., Aarli J.A., et al. Prognostic factors for life expectancy in MS analised by Cox-models. J Clin Epidemiol 1988, 41:1031-1036.
137. Riise T., Gronning M., Fernandez O., et al. Early prognostic factors for disability in MS, a European multicenter study. Acta Neurol Scand 1992, 85:212-218.
138. Rodriguez M., Siva A., Ward J., et al. Impairment, disability, and handicap in MS: a population-based study in Olmsted County, Minnesota. Neurology 1994, 44:28-33.
139. Rudick R., Antel J., Confavreux C., et al. Clinical outcomes assessment in MS. Ann Neurol 1996, 40:469-479.
140. Rudick R., Antel J., Confavreux C., et al. Recommendations from the National MS Society clinical outcomes assessment task force. Ann Neurol 1997, 42:379-382.
141. Runmarker B., Andersen O. Prognostic factors in a MS incidence cohort with twenty five years of follow-up. Brain 1993, 116:117-134.
142. Runmarker B., Andersson C., Oden A., et al. Prediction of outcome in MS based on multivariate models. J Neurol 1994, 241:597-604.
143. Sackett D.L., Haynes R.B., Tugwell P. Clinical epidemiology: a basic science for clinical medicine 1985, 161-162. Little, Brown, Boston.
144. Sadovnick A.D., Eisen R.N., Ebers G.C., et al. Cause of death in patients attending MS clinics. Neurology 1991, 41:1193-1196.
145. Sadovnick A.D., Ebers G.C., Wilson R.W., et al. Life expectancy in patients attending MS clinics. Neurology 1992, 42:991-994.
146. Sayao A.L., Devonshire V., Tremlett H. Longitudinal follow-up of "benign" MS at 20 years. Neurology 2007, 68:496-500.
147. Schumacher G.A., Beebe G., Kibler R.F., et al. Problems of experimental trials of therapy in MS: report by the panel on the evaluation of experimental trials of therapy in MS. Ann N Y Acad Sci 1965, 122:552-568.
148. Simone I.L., Carrara D., Tortorella C., et al. Course and prognosis in early-onset MS: comparison with adult-onset forms. Neurology 2002, 59:1922-1928.
149. Sindern E., Haas J., Stark E., et al. Early onset MS under the age of 16: clinical and paraclinical features. Acta Neurol Scand 1992, 86:280-284.
150. Skoog B., Runmarker B., Andersen O. A 37-50 year follow-up of the Gothenburg MS cohort. Mult Scler 2004, (suppl):P258. p S156.
151. Soderström M., Ya-Ping J., Hillert J., et al. Optic neuritis: prognosis for MS from MRI, CSF, and HLA findings. Neurology 1998, 50:708-714.
152. Stenager E.N., Stenager E., Koch-Henriksen N., et al. Suicide and MS: an epidemiological investigation. J Neurol Neurosurg Psychiatry 1992, 55:542-545.
153. Sumelahti M.L., Tienari P.J., Wikström J., et al. Survival of MS in Finland between 1964 and 1993. Mult Scler 2002, 8:350-355.
154. Thompson A.J., Hutchinson M., Brazil J., et al. A clinical and laboratory study of benign MS. Q J Med 1986, 58:69-80.
155. Thompson A.J., Polman C.H., Miller D.H., et al. Primary progressive MS. Brain 1997, 120:1085-1096.
156. Thygesen P. Disseminated sclerosis: influence of age on the different modes of progression. Acta Psychiatr Neurol Scand 1955, 30:365-374.
157. Tintoré M., Rovira A., Martinez M.J., et al. Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite MS. AJNR Am J Neuroradiol 2000, 21:702-706.
158. Tintoré M., Rovira A., Rio J., et al. New diagnostic criteria for MS. Application in first demyelinating episode. Neurology 2003, 60:27-30.
159. Tintoré M., Rovira A., Rio J., et al. Is optic neuritis more benign than other first attacks in MS?. Ann Neurol 2005, 57:210-215.
160. Tintoré M., Rovira A., Rio J., et al. Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology 2006, 67:968-972.
161. Tremlett H., Paty D., Devonshire V. Disability progression in MS is slower than previously reported. Neurology 2006, 66:172-177.
162. Tremlett H., Zhao Y., Devonshire V. The natural history of secondary progressive MS. Mult Scler 2008, 14:314-324.
163. Trojano M., Avolio C., Manzari C., et al. Multivariate analysis of predictive factors of MS with a validated method to assess clinical events. J Neurol Neurosurg Psychiatry 1995, 58:300-306.
164. Trojano M., Liguori M., Bosco Zimatore G., et al. Age-related disability in MS. Ann Neurol 2002, 51:475-480.
165. Visscher B.R., Liu K.S., Clark V.A., et al. Onset symptoms as predictors of mortality and disability in MS. Acta Neurol Scand 1984, 70:321-328.
166. Vukusic S., Confavreux C. Prognostic factors for progression of disability in the secondary progressive phase of MS. J Neurol Sci 2003, 206:135-137.
167. Vukusic S., Hutchinson M., Hours M., et al. Pregnancy and MS (the PRIMS study): clinical predictors of post-partum relapse. Brain 2004, 127:1353-1360.
168. Wallin M.T., Page W.F., Kurtzke J. Epidemiology of MS in US veterans. VIII. Long-term survival after onset of MS. Brain 2000, 123:1677-1687.
169. Weinshenker B.G. Databases in MS research: pitfalls and promises. Mult Scler 1999, 5:206-211.
170. Weinshenker B.G., Ebers G.C. The natural history of MS. Can J Neurol Sci 1987, 14:255-261.
171. Weinshenker B.G., Bass B., Rice G.P.A., et al. The natural history of MS: a geographically based study. 1. Clinical course and disability. Brain 1989, 112:133-146.
172. Weinshenker B.G., Bass B., Rice G.P.A., et al. The natural history of MS: a geographically based study. 2. Predictive value of the early clinical course. Brain 1989, 112:1419-1428.
173. Weinshenker B.G., Rice G.P.A., Noseworthy J.H., et al. The natural history of MS: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome. Brain 1991, 114:1045-1056.
174. Weinshenker B.G., Rice G.P.A., Noseworthy J.H., et al. The natural history of MS: a geographically based study. 4. Applications to planning and interpretation of clinical trials. Brain 1991, 114:1057-1067.
175. Willoughby E.W., Paty D.W. Scales for rating impairment in MS: a critique. Neurology 1988, 38:1793-1798.
176. Wynn D.R., Rodriguez M., O'Fallon W.M., et al. A reappraisal of the epidemiology of multliple sclerosis in Olmsted County, Minnesota. Neurology 1990, 40:780-786.
177. Youl B.D., Turano G., Miller D.H., et al. The pathophysiology of acute optic neuritis. An association of gadolinium leakage with clinical and electrophysiological deficits. Brain 1991, 114:2437-2450.